Page last updated: 2024-11-05

n-methylpyrrolidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N-methylpyrrolidine is a heterocyclic amine compound with a five-membered ring containing one nitrogen atom. It is a colorless liquid with a pungent odor. N-methylpyrrolidine is a versatile building block in organic synthesis and is used in the preparation of pharmaceuticals, agrochemicals, and other fine chemicals. Its importance lies in its ability to act as a chiral auxiliary, a catalyst, and a reagent in various chemical reactions. For instance, it is employed in asymmetric synthesis, where it promotes the formation of specific enantiomers of chiral molecules, which is crucial for developing drugs and other bioactive compounds. The study of N-methylpyrrolidine is driven by its potential applications in various fields, including medicinal chemistry, catalysis, and materials science.'

N-methylpyrrolidine: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID8454
CHEMBL ID665
MeSH IDM0154972

Synonyms (54)

Synonym
nsc 65579
brn 0102445
einecs 204-438-5
pyrrolidine, n-methyl-
n-methylpyrrolidine
n-methyltetrahydropyrrole
methylpyrrolidine
pyrrolidine, n-methyl
nsc65579
nsc-65579
120-94-5
inchi=1/c5h11n/c1-6-4-2-3-5-6/h2-5h2,1h
1-methylpyrrolidine ,
pyrrolidine, 1-methyl-
n-methylpyrrolidine, 97%
n-methyl pyrrolidine
CHEMBL665
M0415
tox21_301212
dtxsid8042210 ,
dtxcid6022210
NCGC00255880-01
cas-120-94-5
06509tzu6c ,
5-20-01-00166 (beilstein handbook reference)
unii-06509tzu6c
ec 204-438-5
FT-0608097
AKOS015850845
1-methyl-pyrrolidine
S6216
methylpyrrolidine, 1-
cefepime impurity g [ep impurity]
cefepime dihydrochloride monohydrate impurity g [ep impurity]
1-methyl-pyrolidine
n-methyl-pyrrolodine
n-methyl-pyrrolidine
methyl pyrrolidine
n-methylpyrollidine
n-methyl pyrollidine
n-methylpyrolidine
n-methy-lpyrrolidine
n- methylpyrrolidine
n-methylpyrrolidin
pyrrolidine,l-methyl-
W-108468
mfcd00003173
1-methylpyrrolidine, >=98.0% (gc)
F0001-0336
HY-128383
Q22829186
AMY25542
D78045
CS-0099463
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GLI family zinc finger 3Homo sapiens (human)Potency51.52020.000714.592883.7951AID1259369; AID1259392
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency54.94100.000214.376460.0339AID720691
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (12)

Assay IDTitleYearJournalArticle
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID661629Superoxide release activity in potassium phosphate buffer at pH 7.4 and 25 uM after 30 mins by luminol-based colorimetric assay2012Bioorganic & medicinal chemistry letters, Jun-01, Volume: 22, Issue:11
Synthesis, reactive oxygen species generation and copper-mediated nuclease activity profiles of 2-aryl-3-amino-1,4-naphthoquinones.
AID781327pKa (acid-base dissociation constant) as determined by Morgenthaler ref: ChemMedChem 20072014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID30521Compounds was evaluate for their ability to enhance (+/-)-[3H]nicotine binding at a dose range 10 E -10 - 10 E -6 M was reported1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Structure-activity relationships of some pyridine, piperidine, and pyrrolidine analogues for enhancing and inhibiting the binding of (+/-)-[3H]nicotine to the rat brain P2 preparation.
AID30389Ability to enhance the binding of (+/-)-[3H]nicotine to the rat brain P2 fraction at binding site 21985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Structure-activity relationships of some pyridine, piperidine, and pyrrolidine analogues for enhancing and inhibiting the binding of (+/-)-[3H]nicotine to the rat brain P2 preparation.
AID30377Maximum percent of enhancement of binding.1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Structure-activity relationships of some pyridine, piperidine, and pyrrolidine analogues for enhancing and inhibiting the binding of (+/-)-[3H]nicotine to the rat brain P2 preparation.
AID30378Maximum percent of inhibition of binding was determined1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Structure-activity relationships of some pyridine, piperidine, and pyrrolidine analogues for enhancing and inhibiting the binding of (+/-)-[3H]nicotine to the rat brain P2 preparation.
AID661627Hydrogen peroxide release activity in potassium phosphate buffer at pH 7.4 after 60 mins by xylene-orange based colorimetric assay2012Bioorganic & medicinal chemistry letters, Jun-01, Volume: 22, Issue:11
Synthesis, reactive oxygen species generation and copper-mediated nuclease activity profiles of 2-aryl-3-amino-1,4-naphthoquinones.
AID30391Ability to enhance the binding of (+/-)-[3H]nicotine to the rat brain P2 fraction at binding site 3.1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Structure-activity relationships of some pyridine, piperidine, and pyrrolidine analogues for enhancing and inhibiting the binding of (+/-)-[3H]nicotine to the rat brain P2 preparation.
AID30382Compound was evaluated for ability to enhance the binding of (+/-)-[3H]nicotine to the rat brain P2 fraction at binding site 1; 10e-10-10e-61985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Structure-activity relationships of some pyridine, piperidine, and pyrrolidine analogues for enhancing and inhibiting the binding of (+/-)-[3H]nicotine to the rat brain P2 preparation.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (39)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (12.82)18.7374
1990's3 (7.69)18.2507
2000's15 (38.46)29.6817
2010's14 (35.90)24.3611
2020's2 (5.13)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 42.01

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index42.01 (24.57)
Research Supply Index3.74 (2.92)
Research Growth Index5.03 (4.65)
Search Engine Demand Index58.11 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (42.01)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other41 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]